Established in 2015, Xgene Pharmaceutical, Inc. engineers high-impact medications for unmet underserved needs in neurological conditions. Xgene’s proprietary linker technology generates novel dual-acting conjugates combining two well-characterized and efficacious therapeutic molecules to produce a targeted multimodal approach. The conjugated prodrug molecules exhibit different – modified by the linker – absorption, pharmacokinetic, and metabolic characteristics as compared to either parent drug. Preclinical studies of these conjugates demonstrate that the Xgene’s linker modification results in lower toxicity and superior efficacy in several conditions characterized by high unmet need.

Our Vision

Our vision is to develop superior products by leveraging clinical knowledge and basic research to achieve better treatment for patients.

Our Mission

Our mission is to bring more effective, safer products to market with efficient development process.

Leadership Team

Gene Hsu

CEO & Founder

Feng Xu

Chief Operating Officer &

Chief Scientific Officer & Founder

Leon Jiang

Chief Medical Officer & Senior Vice President

Guozhu Zheng

Chief Discovery Officer & Senior Vice President

Lan Hong

Vice President of CMC

Iwona Beczkowska

Head of

Business Development

Gene Hsu

CEO & Founder

Feng Xu

Chief Operating Officer &

Chief Scientific Officer & Founder

Leon Jiang

Chief Medical Officer & Senior Vice President

Guozhu Zheng

Chief Discovery Officer & Senior Vice President

Lan Hong

Vice President of CMC

Iwona Beczkowska

Head of

Business Development

Board Of Directors

Gene Hsu

Chairman

Feng Xu

Director

Stephen H. Ip

Independent Director

Lily Shen

Director

Jayson Lee

Director

Advisory Board

Dr. Stephan A.

Shug

Peter G.

Lacauture

Allen G. Downs

Investors

Xgene has completed 3 rounds of financing: Round A 2016 Q1; Round B 2018 Q4; Round C 2021 Q4.

For more information, contact Dr. Iwona Beczkowska, Exec. Director of Business Development, iwona.beczkowska@xgenepharm.com